Abstract 2827: PD0332991-induced stromal senescence promotes melanoma growth <i>in vivo</i>
Authors: Xiangnan Guan, Kyle Lapak, Rebecca Hennessey, Christin Burd
Journal: Cancer Research (2016)

Abstract Cellular senescence, a process in which cells permanently exit the cell cycle, has pleiotropic biological effects. Several lines of evidence suggest that senescent cells within the tumor microenvironment can elicit a pro-inflammatory secretome that promotes cancer initiation and progression. This proinflammatory phenotype differs amongst senescent cells triggered by distinct stimuli; therefore, multiple forms of senescent cells likely exist within the tumor stroma during cancer evolution and treatment. Here, we sought to determine how stromal senescence initiated by clinically relevant treatments would influence melanoma growth. To generate senescent stromal populations, we treated presenescent MEFs (p4) with ultraviolet light (UV), Mitomycin C (MMC), or a CDK4/6 inhibitor (CDK4/6i). In contrast to p4 fibroblasts, cells treated with UV, MMC or CDK4/6i exhibited cell cycle arrest, increased SA-β-gal positivity and elevated p16INK4a expression. Pronounced 53BP1 and γH2AX foci were only observed in the UV and MMC treated cells, suggesting the CDK4/6i treatment did not induce DNA damage. Profiling of gene expression using a TaqMan mouse inflammation expression panel revealed distinctions amongst the 4 fibroblast lines. Of the senescent cell populations, CDK4/6i fibroblasts showed the highest number of elevated pro-inflammatory transcripts. To define the in vitro paracrine growth effects induced by stromal senescence, melanoma cell lines harboring either Braf600E, Ras, or unknown (wild-type) driver were co-cultured with each fibroblast population. In general, melanoma cells grew similarly on senescent and non-senescent fibroblasts; however, tumor cell growth was genotype-dependent. Notably, CDK4/6i fibroblasts never stimulated additional tumor cell growth in vitro. In contrast, syngeneic transplantations of fibroblasts and tumor cells into immune competent mice revealed that all senescent fibroblasts stimulated tumor growth in vivo. However, whether senescent and non-senescent fibroblasts promoted tumor growth at the same rate was genotype-dependent. Since this is the first study to examine the paracrine effects of senescent stromal cells using an immune competent mouse, we performed IHC for CD45 to assess whether immune cell recruitment differs in the presence of senescent stromal fibroblasts. No increase in CD45 positive infiltrates was observed in the melanoma lines co-injected with CDK4/6i fibroblasts. Together, this work reveals that melanoma growth in response to senescent stromal fibroblasts is genotype dependent, and that this stromal promotion of cancer growth can be accurately assessed only in the context of an immune competent, syngeneic host. Moreover, these data suggest that stromal senescence induced by emerging CDK4/6 inhibitor therapies and/or regimens combining chemotherapy/radiation with immune checkpoint blockade may also promote tumor growth through the paracrine effects of senescent bystanders. Citation Format: Xiangnan Guan, Kyle Lapak, Rebecca Hennessey, Christin Burd. PD0332991-induced stromal senescence promotes melanoma growth in vivo. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 2827.